Medistim ASA (0OCD) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to Medisim's first quarter 2025 results presentation. My name is Kari Kragstad, and together with the CFO, Thomas Jakobsen, we are going to take you through the first quarter's results. And we will start with the highlights. But before that, we like to also remind everyone of Medistim's track record, which has been very positive, showing a consistent delivery of sales growth, profitable sales growth over the years. And as the last 12 months 2025 columns are indicating, we can already from this graph disclose that Q1 was a very strong start to 2025 for the company. So let's go directly into the highlights for the first quarter. This is really a quarter when the business is firing on all cylinders. It is an exceptionally strong sales and EBIT for a quarter, representing a new record for both. 181.5 million NOX in revenues. That's actually 20% higher than our previous record, which we set in the fourth quarter last year. So that ends up with a 35.7% growth in total, which is of course extremely high. We see that we have a little bit help from currency, but still adjusting for that, the total sales is up 31.8%. And as I said, it's really firing on all cylinders. So Americas is up 28%, EMEA is up 18%, Asia Pacific is up almost 63%. And also the third party products is showing fantastic growth this quarter. This is of course also enabling us to deliver a very strong operating profit for the quarter. So 59.2 million, that's actually 84% better than the same quarter last year. And it's very much related to the strong growth that we're seeing in our own products. And we will go into all of these details through the presentation. News from the first quarter, we have worked with strengthening our commercial operations with some organizational changes and adaptations...